Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 264-265

  Zucchini, G ^a   Bernardi, A ^a   Martoni, A ^a   Zamagni, C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

AGED; BREAST METASTASIS; CANCER GROWTH; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GENE OVEREXPRESSION; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; MEDICAL HISTORY; MONOTHERAPY; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

EID: 84871576393     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds596     Document Type: Letter

References (4)

1. Brunello A, Monfardini S, Crivellari D et al. Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>70 years). J Clin Oncol 2008; 26 (Suppl): (Abstr 1096).
2. Paton VE, Klein P, Lieberman G. Trastuzumab (H) benefits both younger and older women with HER2 positive MBC. Proc Am Soc Clin Oncol 2003; 22: (Abstr 294).
3. Fyfe GA, Mass R, Murphy M et al. Survival benefit of trastuzumab (Herceptin) and chemotherapy in older (age >60) patients. Proc Am Soc Clin Oncol 2001; 20: (Abstr 189).
4. Serrano C, Cortés J, De Mattos-Arruda L et al. Trastuzumab related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012; 23: 897-902.